Business Context and Reporting Period
This Form 8-K was filed by Oragenics, Inc. on June 1, 2007, reporting a corporate governance event. The company is incorporated in Florida and operates from Alachua, Florida.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation:
- Base Salary: $100,000 annually for the new Chief Financial Officer.
- Equity Grant: 30,000 shares of common stock, time-vested over two years.
Material Changes
The primary material change is the appointment of Ms. Dorothy Jean (Dotti) Delfino as Chief Financial Officer and Secretary, effective June 1, 2007. She succeeds Mr. Robert T. Zahradnik, who served as Interim Chief Financial Officer and Secretary since May 5, 2006. Ms. Delfino previously served as the Company's Controller since May 2006.
Outlook, Risks, and Management Commentary
Management highlights Ms. Delfino's broad experience in public and university research and development platforms, including prior senior management roles at the University of Florida and national engineering consulting firms. The filing contains no specific guidance, risk factors, or discussion of unusual items beyond the personnel change.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 30,000 stock options granted to the new CFO.
- Confirm the transition timeline for the Interim CFO's departure and the new CFO's assumption of duties.
- Review subsequent filings for any changes to the company's financial reporting structure under the new CFO.